MA26468A1 - Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number: MA26468A1
Authority: MA; Morocco
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; sulfonylurea derivatives; sulfonylurea
Prior art date: 1997-01-29

Application number

MA24947A

Other languages

English (en)

Inventor

Frederick Eggler James

Anthony Dombroski Mark

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-29

Filing date

1998-01-28

Publication date

2004-12-20

1998-01-28 Application filed by Pfizer filed Critical Pfizer

2004-12-20 Publication of MA26468A1 publication Critical patent/MA26468A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

MA24947A 1997-01-29 1998-01-28 Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant MA26468A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3697997P	1997-01-29	1997-01-29

Publications (1)

Publication Number	Publication Date
MA26468A1 true MA26468A1 (fr)	2004-12-20

Family

ID=21891776

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA24947A MA26468A1 (fr)	1997-01-29	1998-01-28	Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (40)

Country	Link
US (2)	US6166064A (fr)
EP (1)	EP0964849B1 (fr)
JP (1)	JP3573757B2 (fr)
KR (1)	KR100324058B1 (fr)
CN (1)	CN1127479C (fr)
AP (1)	AP929A (fr)
AR (1)	AR011093A1 (fr)
AT (2)	ATE242208T1 (fr)
AU (1)	AU723895B2 (fr)
BG (1)	BG103597A (fr)
BR (1)	BR9714328A (fr)
CA (1)	CA2279186C (fr)
CO (1)	CO4920230A1 (fr)
CZ (1)	CZ293173B6 (fr)
DE (2)	DE69722663T2 (fr)
DK (2)	DK0964849T3 (fr)
DZ (1)	DZ2407A1 (fr)
EA (1)	EA001803B1 (fr)
ES (2)	ES2222426T3 (fr)
HR (1)	HRP980045B1 (fr)
HU (1)	HUP0000567A3 (fr)
ID (1)	ID22223A (fr)
IL (1)	IL130855A0 (fr)
IS (1)	IS5099A (fr)
MA (1)	MA26468A1 (fr)
NO (1)	NO313279B1 (fr)
NZ (1)	NZ336248A (fr)
OA (1)	OA11079A (fr)
PA (1)	PA8444701A1 (fr)
PE (1)	PE57898A1 (fr)
PL (1)	PL335052A1 (fr)
PT (2)	PT1270565E (fr)
SK (1)	SK283679B6 (fr)
TN (1)	TNSN98017A1 (fr)
TR (1)	TR199901816T2 (fr)
TW (1)	TW515788B (fr)
UY (1)	UY24861A1 (fr)
WO (1)	WO1998032733A1 (fr)
YU (1)	YU33799A (fr)
ZA (1)	ZA98685B (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6022984A (en) *	1998-07-27	2000-02-08	Pfizer Inc.	Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (fr) *	1998-08-31	2005-11-16	Pfizer Products Inc.	Protéines de liaison pour diarylsulfonylurée
IT1303249B1 (it) *	1998-10-23	2000-11-06	Dompe Spa	Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
EP1214087A1 (fr) *	1999-09-14	2002-06-19	Pfizer Products Inc.	Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (fr) *	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methodes de traitement de maladies et de troubles relies au facteur nucleaire-kappa b
CA2451955C (fr)	2001-06-26	2015-09-29	Abgenix, Inc.	Anticorps opgl
MXPA04001785A (es)	2001-09-14	2004-07-08	Bayer Ag	Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores.
BR0214810A (pt) *	2001-11-30	2004-11-03	Pfizer Prod Inc	Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
US20030131370A1 (en) *	2001-12-14	2003-07-10	Pfizer Inc.	Disruption of the glutathione S-transferase-Omega-1 gene
RU2236677C2 (ru) *	2002-06-24	2004-09-20	Чичкова Марина Александровна	Способ прогнозирования раннего клинического течения экссудативного перикардита у больных с системными заболеваниями
WO2004004725A2 (fr)	2002-07-09	2004-01-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Nouvelles compositions pharmaceutiques a base de nouveaux anticholinergiques et d'inhibiteurs de la kinase p38
CN104178491B (zh)	2002-09-06	2018-07-03	安姆根有限公司	治疗性人抗-il-1r1单克隆抗体
WO2004031777A1 (fr) *	2002-10-03	2004-04-15	Pfizer Products Inc.	Utilisation de gst-omega-2 en tant que cible therapeutique
JP2007512227A (ja)	2003-08-06	2007-05-17	セノミックス、インコーポレイテッド	Ｔ１ｒヘテロオリゴマー味覚受容体、この受容体を発現する細胞株、および味覚化合物
PT1776336E (pt) *	2004-03-23	2009-12-18	Dompe Spa	Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
US20060045953A1 (en) *	2004-08-06	2006-03-02	Catherine Tachdjian	Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
MX2007009388A (es)	2005-02-04	2007-09-25	Senomyx Inc	Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
WO2006090927A1 (fr) *	2005-02-28	2006-08-31	Eisai R & D Management Co., Ltd.	Action orexigenique d'un compose de sulfonamide
US7208526B2 (en) *	2005-05-20	2007-04-24	Hoffmann-La Roche Inc.	Styrylsulfonamides
AR055329A1 (es)	2005-06-15	2007-08-15	Senomyx Inc	Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
EP3235811B1 (fr)	2006-04-21	2018-07-25	Senomyx, Inc.	Procédé de production d'amides oxaliques
EP1992344A1 (fr)	2007-05-18	2008-11-19	Institut Curie	P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
US7973051B2 (en) *	2007-11-30	2011-07-05	Hoffman-La Roche Inc.	Aminothiazoles as FBPase inhibitors for diabetes
WO2014078568A1 (fr)	2012-11-14	2014-05-22	The Johns Hopkins University	Méthodes et compositions pour le traitement de la schizophrénie
EP3180312B1 (fr)	2014-08-12	2019-10-16	Loyola University Of Chicago	Inhibiteurs indoline-sulfonamide de dape et ndm-1 et utilisation de ceux-ci
HUE055755T2 (hu) *	2015-02-16	2021-12-28	Univ Queensland	Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
US10688077B2 (en) *	2015-02-26	2020-06-23	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr)	2016-01-25	2018-03-02	Galderma Research & Development	Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
HK1257569A1 (zh)	2016-02-16	2019-10-25	The University Of Queensland	磺醯脲和相关化合物及其用途
US11339136B2 (en)	2016-04-18	2022-05-24	Novartis Ag	Compounds and compositions for treating conditions associated with NLRP activity
WO2017184604A1 (fr) *	2016-04-18	2017-10-26	Ifm Therapeutics, Inc	Composés et compositions destinés au traitement d'états associés à une activité de nlrp
EP3272739A1 (fr) *	2016-07-20	2018-01-24	NodThera Limited	Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
US20220267260A1 (en) *	2016-11-29	2022-08-25	Epizyme, Inc.	Compounds containing a sulfonic group as kat inhibitors
CA3047336A1 (fr)	2017-01-23	2018-07-26	Jecure Therapeutics, Inc.	Composes chimiques comme inhibiteurs de l'activite interleukine-1
US11840543B2 (en)	2017-05-24	2023-12-12	The University Of Queensland	Compounds and uses
US11236045B2 (en)	2017-06-09	2022-02-01	Cadila Healthcare Limited	Substituted sulfoximine compounds
EP3649112A1 (fr)	2017-07-07	2020-05-13	Inflazome Limited	Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
KR102669722B1 (ko)	2017-07-07	2024-05-29	인플라좀 리미티드	신규한 설폰아마이드 카복스아마이드 화합물
HUE066566T2 (hu)	2017-07-24	2024-08-28	Novartis Ag	Vegyületek és készítmények NLRP aktivitással összefüggõ állapotok kezelésére
EP3668843A1 (fr)	2017-08-15	2020-06-24	Inflazome Limited	Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
TW201910317A (zh)	2017-08-15	2019-03-16	愛爾蘭商英弗雷佐姆有限公司	新穎化合物
TW201910316A (zh)	2017-08-15	2019-03-16	愛爾蘭商英弗雷佐姆有限公司	新穎化合物
EP3668840A1 (fr)	2017-08-15	2020-06-24	Inflazome Limited	Nouveaux composés de sulfonamide carboxamide
US11773058B2 (en)	2017-08-15	2023-10-03	Inflazome Limited	Sulfonamide carboxamide compounds
WO2019043610A1 (fr)	2017-08-31	2019-03-07	Cadila Healthcare Limited	Nouveaux dérivés de sulfonylurées substitués
US11623922B2 (en)	2017-10-03	2023-04-11	Inflazome Limited	Compounds
JP7157804B2 (ja) *	2017-10-17	2022-10-20	ノバルティスアーゲー	Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物
PE20210050A1 (es)	2017-11-09	2021-01-08	Inflazome Ltd	Nuevos compuestos de sulfonamida carboxamida
EP3707137A1 (fr)	2017-11-09	2020-09-16	Inflazome Limited	Nouveaux composés de sulfonamide carboxamide
GB201721185D0 (en)	2017-12-18	2018-01-31	Nodthera Ltd	Sulphonyl urea derivatives
CN108299256B (zh) *	2018-01-09	2019-09-10	武汉大学	一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
WO2019166627A1 (fr)	2018-03-02	2019-09-06	Inflazome Limited	Nouveaux composés
US11884645B2 (en)	2018-03-02	2024-01-30	Inflazome Limited	Sulfonyl acetamides as NLRP3 inhibitors
US11530200B2 (en)	2018-03-02	2022-12-20	Inflazome Limited	Compounds
WO2019166619A1 (fr)	2018-03-02	2019-09-06	Inflazome Limited	Nouveaux composés
EP3759073A1 (fr)	2018-03-02	2021-01-06	Inflazome Limited	Dérivés de sulfonamide utilisés en tant qu'inhibiteurs de nlrp3
US12030879B2 (en)	2018-03-02	2024-07-09	Inflazome Limited	Sulfonyl acetamides as NLRP3 inhibitors
US20220267276A1 (en) *	2018-07-03	2022-08-25	Novartis Ag	Nlrp modulators
CA3104199A1 (fr) *	2018-07-20	2020-01-23	F. Hoffmann-La Roche Ag	Composes de sulfonyluree en tant qu'inhibiteurs de l'activite de l'interleukine 1
BR112021001044A2 (pt)	2018-07-20	2021-04-13	F. Hoffmann-La Roche Ag	Compostos de sulfonimidamida como inibidores da atividade de interleucina-1
WO2020035482A1 (fr)	2018-08-13	2020-02-20	Iltoo Pharma	Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
CN112672995A (zh)	2018-08-15	2021-04-16	英夫拉索姆有限公司	新型磺酰胺脲化合物
CN113056451A (zh) *	2018-10-24	2021-06-29	诺华股份有限公司	用于治疗与nlrp活性相关的病症的化合物和组合物
FI3911631T3 (fi)	2019-01-14	2025-02-03	Zydus Lifesciences Ltd	Uusia substituoituja sulfonyyliureajohdannaisia
ES3056339T3 (en)	2019-06-12	2026-02-19	Nodthera Ltd	Sulfonylurea derivatives and uses thereof
SI3983387T1 (sl)	2019-06-12	2024-09-30	NodThera Limited	Derivati sulfoniluree in njihove uporabe
EP3986879B1 (fr)	2019-06-21	2024-10-02	AC Immune SA	1,2-thiazoles et 1,2-thiazines fusionnés qui agissent en tant que modulateurs de nlrp3
US12377070B2 (en)	2019-09-12	2025-08-05	Zydus Lifesciences Limited	Substituted sulfoximine derivatives
JP7843705B2 (ja)	2020-01-22	2026-04-10	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
JP7504234B2 (ja) *	2020-06-11	2024-06-21	シーセンファーマシューティカルカンパニーリミテッド	ジメチルスルホキシミン誘導体
IL299084A (en)	2020-06-19	2023-02-01	Ac Immune Sa	History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
WO2022022646A1 (fr) *	2020-07-29	2022-02-03	南京明德新药研发有限公司	Composé cyclique hétéroaromatique à cinq chaînons contenant du sélénium
IL301055A (en)	2020-09-04	2023-05-01	Nodthera Ltd	Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
ES2948511A1 (es) *	2021-09-08	2023-09-13	Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa	Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (fr) *	2021-12-03	2023-06-08	南京明德新药研发有限公司	Forme saline et forme cristalline de dérivé de diméthyl sulfoximine
US20250109126A1 (en)	2021-12-22	2025-04-03	Ac Immune Sa	Dihydro-oxazol derivative compounds
AU2023220628A1 (en) *	2022-02-15	2024-05-23	F. Hoffmann-La Roche Ag	Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
EP4526469A1 (fr)	2022-05-16	2025-03-26	Institut National de la Santé et de la Recherche Médicale	Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique
EP4554945A1 (fr)	2022-07-14	2025-05-21	AC Immune SA	Dérivés de pyrrolotriazine et d'imidazotriazine utilisés en tant que modulateurs de la voie de l'inflammasome nlrp3
CA3261365A1 (fr)	2022-07-28	2024-02-01	Ac Immune Sa	Nouveaux composés
WO2025133307A1 (fr)	2023-12-22	2025-06-26	Ac Immune Sa	Modulateurs hétérocycliques de la voie de l'inflammasome nlrp3
WO2025153532A1 (fr)	2024-01-16	2025-07-24	NodThera Limited	Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1
WO2025153625A1 (fr)	2024-01-17	2025-07-24	Ac Immune Sa	Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025153624A1 (fr)	2024-01-17	2025-07-24	Ac Immune Sa	Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025163069A1 (fr)	2024-01-31	2025-08-07	Ac Immune Sa	Nouveaux composés
CN118638081B (zh) *	2024-05-23	2026-05-08	武汉科技大学	磺酰脲类化合物
WO2025251275A1 (fr) *	2024-06-07	2025-12-11	上海麦克林生化科技股份有限公司	Procédé de préparation d'un nouveau composé benzylsulfinylpyridine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4586950A (en) *	1982-05-31	1986-05-06	E. I. Du Pont De Nemours & Company	Novel phenyl-substituted sulfonamides
US4780125A (en) *	1982-09-01	1988-10-25	Ciba-Geigy Corporation	N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) *	1989-08-19	1991-02-21	Bayer Ag	Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) *	1990-07-24	1991-11-12	Pfizer Inc.	3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) *	1991-10-15	1993-10-19	Warner-Lambert Company	Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) *	1993-12-30	1995-07-06	Hoechst Ag	Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) *	1994-12-07	1998-06-10	南开大学	磺酰脲类化合物及其除草用途
HU226462B1 (en) *	1995-02-17	2008-12-29	Hoechst Ag	Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
US6281240B1 (en) *	1997-04-10	2001-08-28	Eli Lilly And Company	Diarylsulfonylureas for use in treating secretory diarrhea

1997
- 1997-12-29 JP JP51868798A patent/JP3573757B2/ja not_active Expired - Fee Related
- 1997-12-29 ES ES02020749T patent/ES2222426T3/es not_active Expired - Lifetime
- 1997-12-29 ID IDW990764A patent/ID22223A/id unknown
- 1997-12-29 SK SK982-99A patent/SK283679B6/sk unknown
- 1997-12-29 TR TR1999/01816T patent/TR199901816T2/xx unknown
- 1997-12-29 WO PCT/IB1997/001603 patent/WO1998032733A1/fr not_active Ceased
- 1997-12-29 AT AT97947201T patent/ATE242208T1/de not_active IP Right Cessation
- 1997-12-29 HU HU0000567A patent/HUP0000567A3/hu unknown
- 1997-12-29 CA CA002279186A patent/CA2279186C/fr not_active Expired - Fee Related
- 1997-12-29 US US09/341,782 patent/US6166064A/en not_active Expired - Fee Related
- 1997-12-29 PT PT02020749T patent/PT1270565E/pt unknown
- 1997-12-29 NZ NZ336248A patent/NZ336248A/xx unknown
- 1997-12-29 BR BR9714328A patent/BR9714328A/pt not_active Application Discontinuation
- 1997-12-29 PT PT97947201T patent/PT964849E/pt unknown
- 1997-12-29 CZ CZ19992575A patent/CZ293173B6/cs not_active IP Right Cessation
- 1997-12-29 CN CN97181579A patent/CN1127479C/zh not_active Expired - Fee Related
- 1997-12-29 KR KR1019997006786A patent/KR100324058B1/ko not_active Expired - Fee Related
- 1997-12-29 EA EA199900603A patent/EA001803B1/ru not_active IP Right Cessation
- 1997-12-29 DK DK97947201T patent/DK0964849T3/da active
- 1997-12-29 DE DE69722663T patent/DE69722663T2/de not_active Expired - Fee Related
- 1997-12-29 AU AU52340/98A patent/AU723895B2/en not_active Ceased
- 1997-12-29 IL IL13085597A patent/IL130855A0/xx unknown
- 1997-12-29 AT AT02020749T patent/ATE270285T1/de not_active IP Right Cessation
- 1997-12-29 EP EP97947201A patent/EP0964849B1/fr not_active Expired - Lifetime
- 1997-12-29 DE DE69729762T patent/DE69729762T2/de not_active Expired - Fee Related
- 1997-12-29 YU YU33799A patent/YU33799A/sh unknown
- 1997-12-29 DK DK02020749T patent/DK1270565T3/da active
- 1997-12-29 PL PL97335052A patent/PL335052A1/xx unknown
- 1997-12-29 ES ES97947201T patent/ES2198598T3/es not_active Expired - Lifetime
1998
- 1998-01-16 PA PA19988444701A patent/PA8444701A1/es unknown
- 1998-01-20 UY UY24861A patent/UY24861A1/es unknown
- 1998-01-23 PE PE1998000051A patent/PE57898A1/es not_active Application Discontinuation
- 1998-01-26 TW TW087101087A patent/TW515788B/zh not_active IP Right Cessation
- 1998-01-27 HR HR980045A patent/HRP980045B1/xx not_active IP Right Cessation
- 1998-01-27 DZ DZ980017A patent/DZ2407A1/fr active
- 1998-01-27 AR ARP980100358A patent/AR011093A1/es not_active Application Discontinuation
- 1998-01-28 TN TNTNSN98017A patent/TNSN98017A1/fr unknown
- 1998-01-28 MA MA24947A patent/MA26468A1/fr unknown
- 1998-01-28 ZA ZA9800685A patent/ZA98685B/xx unknown
- 1998-01-29 CO CO98004326A patent/CO4920230A1/es unknown
- 1998-01-29 AP APAP/P/1998/001190A patent/AP929A/en active
1999
- 1999-06-29 IS IS5099A patent/IS5099A/is unknown
- 1999-07-22 BG BG103597A patent/BG103597A/bg unknown
- 1999-07-23 OA OA9900165A patent/OA11079A/en unknown
- 1999-07-28 NO NO19993658A patent/NO313279B1/no not_active IP Right Cessation
2000
- 2000-10-31 US US09/703,142 patent/US6433009B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA001803B1 (ru)	2001-08-27
CA2279186C (fr)	2004-02-24
ES2198598T3 (es)	2004-02-01
YU33799A (sh)	2002-03-18
US6433009B1 (en)	2002-08-13
CN1127479C (zh)	2003-11-12
AP929A (en)	2001-01-18
ZA98685B (en)	1999-07-29
CO4920230A1 (es)	2000-05-29
IS5099A (is)	1999-06-29
EP0964849B1 (fr)	2003-06-04
ATE270285T1 (de)	2004-07-15
PT964849E (pt)	2003-08-29
BR9714328A (pt)	2000-03-21
CA2279186A1 (fr)	1998-07-30
EA199900603A1 (ru)	2000-02-28
ATE242208T1 (de)	2003-06-15
AU723895B2 (en)	2000-09-07
DE69722663D1 (de)	2003-07-10
DK0964849T3 (da)	2003-08-25
PE57898A1 (es)	1999-06-11
UY24861A1 (es)	2000-09-29
US6166064A (en)	2000-12-26
CZ293173B6 (cs)	2004-02-18
BG103597A (bg)	2000-02-29
SK283679B6 (sk)	2003-11-04
TR199901816T2 (xx)	1999-11-22
EP0964849A1 (fr)	1999-12-22
KR100324058B1 (ko)	2002-02-16
ES2222426T3 (es)	2005-02-01
NO313279B1 (no)	2002-09-09
PL335052A1 (en)	2000-03-27
CN1245490A (zh)	2000-02-23
WO1998032733A1 (fr)	1998-07-30
DK1270565T3 (da)	2004-10-04
SK98299A3 (en)	2001-10-08
HRP980045B1 (en)	2002-10-31
ID22223A (id)	1999-09-16
KR20000070541A (ko)	2000-11-25
AU5234098A (en)	1998-08-18
NO993658D0 (no)	1999-07-28
HUP0000567A3 (en)	2002-10-28
OA11079A (en)	2002-03-14
PT1270565E (pt)	2004-09-30
TNSN98017A1 (fr)	2005-03-15
CZ257599A3 (cs)	2000-09-13
PA8444701A1 (es)	2000-05-24
JP3573757B2 (ja)	2004-10-06
IL130855A0 (en)	2001-01-28
DZ2407A1 (fr)	2003-01-04
JP2000511200A (ja)	2000-08-29
DE69729762T2 (de)	2005-07-14
DE69722663T2 (de)	2004-04-29
DE69729762D1 (de)	2004-08-05
AR011093A1 (es)	2000-08-02
NZ336248A (en)	2000-10-27
HRP980045A2 (en)	1999-06-30
NO993658L (no)	1999-09-28
HUP0000567A2 (hu)	2000-10-28
AP9801190A0 (en)	1998-03-31
TW515788B (en)	2003-01-01

Publication	Publication Date	Title
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26424A1 (fr)	2004-12-20	Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26479A1 (fr)	2004-12-20	Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26499A1 (fr)	2004-12-20	Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26687A1 (fr)	2004-12-20	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26465A1 (fr)	2004-12-20	Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2735777B1 (fr)	1997-09-12	Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
MA26526A1 (fr)	2004-12-20	Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26558A1 (fr)	2004-12-20	Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26425A1 (fr)	2004-12-20	Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26438A1 (fr)	2004-12-20	Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2740136B1 (fr)	1998-01-09	Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26505A1 (fr)	2004-12-20	Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26471A1 (fr)	2004-12-20	Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26415A1 (fr)	2004-12-20	Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr)	2004-12-20	Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr)	2004-12-20	Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
MA26519A1 (fr)	2004-12-20	Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26490A1 (fr)	2004-12-20	Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.